Rocket Pharmaceuticals

$56.14
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.56 (+1.01%) As of 3:56 PM UTC today

Why Robinhood?

You can buy or sell RCKT and other stocks, options, and ETFs commission-free!

About RCKT

Rocket Pharmaceuticals, Inc. Common Stock, also called Rocket Pharmaceuticals, is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY. The listed name for RCKT is Rocket Pharmaceuticals, Inc. Common Stock.

CEO
Gaurav Shah
Employees
57
Headquarters
New York, New York
Founded
—
Market Cap
3.59B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
512.63K
High Today
$58.71
Low Today
$56.14
Open Price
$56.30
Volume
58.26K
52 Week High
$67.48
52 Week Low
$9.01

RCKT Earnings

-$1.08
-$0.72
-$0.36
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
-$1.08 per share

You May Also Like

THG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure